Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers.

[1]  J. T. Zilfou,et al.  Circumvention of P-glycoprotein-mediated Multiple Drug Resistance by Phosphorylation Modulators Is Independent of Protein Kinases (*) , 1995, The Journal of Biological Chemistry.

[2]  R. Fine,et al.  Partial Inhibition of Multidrug Resistance by Safingol Is Independent of Modulation of P-glycoprotein Substrate Activities and Correlated with Inhibition of Protein Kinase C (*) , 1995, The Journal of Biological Chemistry.

[3]  M. Raschack,et al.  Structure-activity relationship of verapamil analogs and reversal of multidrug resistance. , 1995, Biochemical pharmacology.

[4]  C. Higgins,et al.  The ABC of channel regulation , 1995, Cell.

[5]  S. Dei,et al.  Reversal of multidrug resistance by verapamil analogues. , 1995, Biochemical pharmacology.

[6]  W. Wilson,et al.  Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Cordon-Cardo,et al.  Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Ognibene,et al.  Effect of R-verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Wilson,et al.  Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Osann,et al.  Comparison of cyclosporin A, verapamil, PSC-833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. , 1995, Leukemia research.

[11]  J. Robert,et al.  Azelastine and flezelastine as reversing agents of multidrug resistance: pharmacological and molecular studies. , 1995, Biochemical pharmacology.

[12]  T. Tsuruo,et al.  Novel dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro. , 1995, Biochemical pharmacology.

[13]  V. Ling,et al.  Reconstitution of Drug Transport by Purified P-glycoprotein (*) , 1995, The Journal of Biological Chemistry.

[14]  G Ecker,et al.  Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance. , 1995, Journal of medicinal chemistry.

[15]  N. Dodic,et al.  Synthesis and activity against multidrug resistance in Chinese hamster ovary cells of new acridone-4-carboxamides. , 1995, Journal of medicinal chemistry.

[16]  A. Newland,et al.  Circumvention of P‐glycoprotein‐mediated drug resistance in human leukaemic cells by non‐immunosuppressive cyclosporin D analogue, SDZ PSC 833 , 1995, British journal of haematology.

[17]  W. Hait,et al.  Involvement of phospholipase C in heat-shock-induced phosphorylation of P-glycoprotein in multidrug resistant human breast cancer cells. , 1995, Biochemical and biophysical research communications.

[18]  B. Sikic,et al.  Drug resistance in clinical oncology and hematology. Introduction. , 1995, Hematology/oncology clinics of North America.

[19]  J. Ford,et al.  Modulators of multidrug resistance. Preclinical studies. , 1995, Hematology/oncology clinics of North America.

[20]  B. Sikic,et al.  Clinical studies with modulators of multidrug resistance. , 1995, Hematology/oncology clinics of North America.

[21]  R. Arceci,et al.  Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. , 1995, British Journal of Cancer.

[22]  I. Pastan,et al.  Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. , 1995, Cancer research.

[23]  C. Higgins,et al.  Interaction of tamoxifen with the multidrug resistance P-glycoprotein. , 1995, British Journal of Cancer.

[24]  I. Pastan,et al.  Localization of the forskolin labeling sites to both halves of P-glycoprotein: similarity of the sites labeled by forskolin and prazosin. , 1994, Molecular pharmacology.

[25]  C. Smith,et al.  Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. , 1994, Cancer research.

[26]  T. Tsuruo,et al.  Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. , 1994, Blood.

[27]  P. Gros,et al.  Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. , 1994, Biochemistry.

[28]  P. Gros,et al.  Functional expression of P-glycoproteins in secretory vesicles. , 1994, The Journal of biological chemistry.

[29]  D. Clarke,et al.  Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. , 1994, The Journal of biological chemistry.

[30]  C. Higgins.  P-Glycoprotein: To flip or not to flip? , 1994, Current Biology.

[31]  V. Ling,et al.  ATPase activity of purified and reconstituted P-glycoprotein from Chinese hamster ovary cells. , 1994, The Journal of biological chemistry.

[32]  S. Bicknell,et al.  Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft. , 1994, Biochemical pharmacology.

[33]  F. Leonessa,et al.  Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. , 1994, Cancer research.

[34]  R. Boer,et al.  Influence of dexniguldipine-HC1 on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers. , 1994, European journal of cancer.

[35]  C. Smith,et al.  Reversal of multiple drug resistance by tolyporphin, a novel cyanobacterial natural product. , 1994, Oncology research.

[36]  W. Hait,et al.  Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. , 1994, Oncology research.

[37]  D. Y. Thomas,et al.  Functional expression of P-glycoprotein in Saccharomyces cerevisiae confers cellular resistance to the immunosuppressive and antifungal agent FK520. , 1994, Molecular and cellular biology.

[38]  P. Gros,et al.  Functional expression of P-glycoprotein encoded by the mouse mdr3 gene in yeast cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. Sharom,et al.  Functional reconstitution of drug transport and ATPase activity in proteoliposomes containing partially purified P-glycoprotein. , 1993, The Journal of biological chemistry.

[40]  P. Gros,et al.  Functional expression of mouse mdr1 in Escherichia coli. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[42]  A. Harris,et al.  Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. , 1993, British Journal of Cancer.

[43]  M. Stevenson,et al.  Inducers of the heat shock response stimulate phospholipase C and phospholipase A2 activity in mammalian cells , 1993, Journal of cellular physiology.

[44]  Y. Cheng,et al.  BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. , 1993, Cancer research.

[45]  F. Loor,et al.  Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446. , 1993, Journal of the National Cancer Institute.

[46]  S. Carmeli,et al.  Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.

[47]  D. Clarke,et al.  Functional consequences of proline mutations in the predicted transmembrane domain of P-glycoprotein. , 1993, The Journal of biological chemistry.

[48]  M. Reiss,et al.  Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. , 1993, Biochemical pharmacology.

[49]  D. Fabbro,et al.  Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. , 1993, The Journal of biological chemistry.

[50]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[51]  R Hori,et al.  Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. , 1992, The Journal of biological chemistry.

[52]  G. C. Yeh,et al.  A new functional role for P-glycoprotein: efflux pump for benzo(alpha)pyrene in human breast cancer MCF-7 cells. , 1992, Cancer research.

[53]  I. Pastan,et al.  Characterization of the azidopine and vinblastine binding site of P-glycoprotein. , 1992, The Journal of biological chemistry.

[54]  M. Weir,et al.  EVIDENCE THAT THE ANTIPROLIFERATIVE EFFECT OF VERAPAMIL ON AFFERENT AND EFFERENT IMMUNE RESPONSES IS INDEPENDENT OF CALCIUM CHANNEL INHIBITION , 1992, Transplantation.

[55]  S. Howell,et al.  Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. , 1992, Cancer research.

[56]  S. Takao,et al.  Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo- 1,3,2-dioxaphosphorinan-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3 -pyridinecarboxylate on reversing in vivo resistance of tumor cells to adriamycin. , 1992, Cancer research.

[57]  M. Dietel,et al.  Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. , 1992, Biochemical pharmacology.

[58]  S. Gollapudi,et al.  Protein kinase C isoforms in multidrug resistant P388/ADR cells: a possible role in daunorubicin transport. , 1992, Cancer letters.

[59]  A. Pourtier-Manzanedo,et al.  SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance. , 1992, British Journal of Cancer.

[60]  W. Hait,et al.  Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C. , 1991, Molecular pharmacology.

[61]  G. Laurent,et al.  Reversal of multidrug resistance by calcium channel blocker SR33557 without photoaffinity labeling of P-glycoprotein. , 1991, The Journal of biological chemistry.

[62]  I. Tamai,et al.  Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells. , 1991, The Journal of biological chemistry.

[63]  A. Pourtier-Manzanedo,et al.  Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. , 1991, Experimental cell research.

[64]  E. Krebs,et al.  Consensus sequences as substrate specificity determinants for protein kinases and protein phosphatases. , 1991, The Journal of biological chemistry.

[65]  D. Fan,et al.  In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. , 1991, Molecular pharmacology.

[66]  L. Takemoto,et al.  Analysis of P-glycoprotein phosphorylation in HL60 cells isolated for resistance to vincristine. , 1991, The Journal of biological chemistry.

[67]  T. Furukawa,et al.  Glycosylation of P-glycoprotein in a multidrug-resistant KB cell line, and in the human tissues. , 1991, Biochimica et biophysica acta.

[68]  I. Fidler,et al.  Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro. , 1991, Biochemical pharmacology.

[69]  P. Gros,et al.  Multidrug resistance: a novel class of membrane-associated transport proteins is identified. , 1991, Cancer investigation.

[70]  B. Kemp,et al.  Protein kinase recognition sequence motifs. , 1990, Trends in biochemical sciences.

[71]  J. M. Ford,et al.  Pharmacology of drugs that alter multidrug resistance in cancer. , 1990, Pharmacological reviews.

[72]  D. Cohen,et al.  Differential transport properties of two mdr gene products are distinguished by progesterone. , 1990, The Journal of biological chemistry.

[73]  T. Chambers,et al.  Correlation of protein kinase C translocation, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. , 1990, Biochemical and biophysical research communications.

[74]  J. Zalcberg,et al.  Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. , 1990, Cancer research.

[75]  T. Chambers,et al.  Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. , 1990, The Journal of biological chemistry.

[76]  A. Harris,et al.  Enhancement of Adriamycin cytotoxicity in a multidrug resistant Chinese hamster ovary (CHO) subline, CHO-Adrr, by toremifene and its modulation by alpha 1 acid glycoprotein. , 1990, European journal of cancer.

[77]  I. Pastan,et al.  Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. , 1990, Cancer research.

[78]  S. Kaye,et al.  The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. , 1990, Biochemical pharmacology.

[79]  P. Hiestand,et al.  Overcoming multidrug resistance in Chinese hamster ovary cells in vitro by cyclosporin A (Sandimmune) and non-immunosuppressive derivatives. , 1989, British Journal of Cancer.

[80]  S. Keyes,et al.  Enhancement of anthracycline growth inhibition in parent and multidrug-resistant Chinese hamster ovary cells by cyclosporin A and its analogues. , 1989, Cancer research.

[81]  A. W. Boersma,et al.  Effects of cyclosporin a and verapamil on the intracellular daunorubicin accumulation in chinese hamster ovary cells with increasing levels of drug‐resistance , 1989, International journal of cancer.

[82]  I. Pastan,et al.  Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia , 1989, Molecular and cellular biology.

[83]  B. Ryffel,et al.  Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. , 1989, Molecular pharmacology.

[84]  T. Tsuruo,et al.  Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. , 1989, Cancer research.

[85]  C. Benz,et al.  Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  S. Howell,et al.  Dipyridamole enhancement of etoposide sensitivity. , 1989, Cancer research.

[87]  R. Johnstone,et al.  Enhanced efflux of [3H]vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the mdr1 gene. , 1989, Cancer research.

[88]  H L Pearce,et al.  Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[89]  S. Howell,et al.  Comparison of the synergistic potentiation of etoposide, doxorubicin, and vinblastine cytotoxicity by dipyridamole. , 1989, Cancer research.

[90]  G. Duggin,et al.  Cyclosporin A inhibits protein kinase C activity: a contributing mechanism in the development of nephrotoxicity? , 1989, Biochemical and biophysical research communications.

[91]  T. Tsuruo,et al.  Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. , 1989, Cancer research.

[92]  Robert,et al.  Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. , 1989, The Journal of biological chemistry.

[93]  W. Hait,et al.  Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. , 1989, Molecular pharmacology.

[94]  M. Morin,et al.  Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance. , 1989, Cancer communications.

[95]  M. B. Meyers.  Protein phosphorylation in multidrug resistant Chinese hamster cells. , 1989, Cancer communications.

[96]  A. Safa.  Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[97]  W. T. Beck,et al.  Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. , 1988, Biochemical and biophysical research communications.

[98]  D. Housman,et al.  The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[99]  W. Mellado,et al.  Azidopine photoaffinity labeling of multidrug resistance-associated glycoproteins. , 1988, Biochemical pharmacology.

[100]  H L Pearce,et al.  Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. , 1988, Molecular pharmacology.

[101]  H. Parnes,et al.  Studies of high-dose megestrol acetate: potential applications in cachexia. , 1988, Seminars in oncology.

[102]  C. Peterson,et al.  D‐verapamil and L‐verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro , 1988, International journal of cancer.

[103]  I. Pastan,et al.  Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of P-glycoprotein by a vinblastine analog. , 1988, Molecular pharmacology.

[104]  R. Fine,et al.  Phorbol esters induce multidrug resistance in human breast cancer cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[105]  W. Mellado,et al.  Phosphorylation of the multidrug resistance associated glycoprotein. , 1987, Biochemistry.

[106]  N. Fox,et al.  Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line. , 1987, British Journal of Cancer.

[107]  A. Safa,et al.  Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. , 1987, The Journal of biological chemistry.

[108]  T. Tsuruo,et al.  Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. , 1987, Cancer research.

[109]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[110]  Y. Ostchega,et al.  Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  I. Pastan,et al.  Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. , 1987, The Journal of biological chemistry.

[112]  Y. Cheng,et al.  Transient protection of cultured human cells against antitumor agents by 12-O-tetradecanoylphorbol-13-acetate. , 1987, Cancer research.

[113]  D. Housman,et al.  Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins , 1986, Cell.

[114]  Michael M. Gottesman,et al.  Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells , 1986, Cell.

[115]  D. Housman,et al.  Isolation and expression of a complementary DNA that confers multidrug resistance , 1986, Nature.

[116]  S. Gupta,et al.  Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. , 1986, British journal of cancer.

[117]  G. Hahn,et al.  Rapid increases in inositol trisphosphate and intracellular Ca++ after heat shock. , 1986, Biochemical and biophysical research communications.

[118]  R. Ganapathi,et al.  Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine. , 1986, Biochemical pharmacology.

[119]  B. Chauffert,et al.  Amiodarone-induced enhancement of doxorubicin and 4'-deoxydoxorubicin cytotoxicity to rat colon cancer cells in vitro and in vivo. , 1986, Cancer research.

[120]  H. Hidaka,et al.  An inhibitor of protein kinase C, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine(H-7) inhibits TPA-induced reduction of vincristine uptake from P388 murine leukemic cell. , 1986, Leukemia research.

[121]  J. Grem,et al.  Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. , 1985, Cancer research.

[122]  D. Kessel,et al.  Promotion of daunorubicin uptake and toxicity by the calcium antagonist tiapamil and its analogs. , 1985, Cancer treatment reports.

[123]  I. Weinstein,et al.  Inhibition of protein kinase C by tamoxifen. , 1985, Cancer research.

[124]  P. Molinoff,et al.  Assay of dopamine receptors with [alpha-3H]flupenthixol. , 1985, The Journal of pharmacology and experimental therapeutics.

[125]  R. Ganapathi,et al.  Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells. , 1984, Cancer research.

[126]  T. Tsuruo,et al.  Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. , 1984, Cancer research.

[127]  Z. Fuks,et al.  Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. , 1984, Cancer research.

[128]  H. Rahamimoff,et al.  Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells. , 1984, British Journal of Cancer.

[129]  S. Drake,et al.  Potentiation of methotrexate toxicity by dipyridamole. , 1984, Cancer research.

[130]  J. Riordan,et al.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. , 1983, Science.

[131]  T. Tsuruo,et al.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. , 1983, Cancer research.

[132]  T. Tsuruo,et al.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. , 1983, Cancer research.

[133]  V. Jordan,et al.  Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer. , 1983, Cancer research.

[134]  T. Tsuruo,et al.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. , 1982, Cancer research.

[135]  W. T. Beck,et al.  Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase. , 1982, Cancer research.

[136]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[137]  R. Schatzman,et al.  Phospholipid-sensitive calcium-dependent protein kinase: inhibition by antipsychotic drugs. , 1981, Biochemical and biophysical research communications.

[138]  Y. Nishizuka,et al.  Inhibitory action of chlorpromazine, dibucaine, and other phospholipid-interacting drugs on calcium-activated, phospholipid-dependent protein kinase. , 1980, The Journal of biological chemistry.

[139]  T. Skovsgaard.  Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. , 1978, Cancer research.

[140]  T. Crow,et al.  MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA , 1978, The Lancet.

[141]  J. Till,et al.  Modulation of drug permeability in Chinese hamster ovary cells. Possible role for phosphorylation of surface glycoproteins. , 1977, Biochimica et biophysica acta.

[142]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[143]  M. Post,et al.  Stereoselective blockade of the dopamine receptor and the X-ray structures of α and β-flupenthixol , 1975, Nature.

[144]  K. Danø.  Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. , 1973, Biochimica et biophysica acta.

[145]  J. L. Biedler,et al.  Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. , 1970, Cancer research.